Catalyst Biosciences Inc (CBIO) Receives Average Rating of “Strong Buy” from Brokerages

Catalyst Biosciences Inc (NASDAQ:CBIO) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus price objective of $57.00 for the company and are expecting that the company will post ($1.41) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Catalyst Biosciences an industry rank of 195 out of 265 based on the ratings given to related companies.

A number of equities analysts recently weighed in on CBIO shares. ValuEngine upgraded shares of Catalyst Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Zacks Investment Research upgraded shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research report on Wednesday, November 8th. B. Riley set a $19.00 price objective on shares of Catalyst Biosciences and gave the company a “buy” rating in a research report on Monday, December 18th. Finally, Chardan Capital increased their price objective on shares of Catalyst Biosciences from $10.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, February 9th.

A number of hedge funds have recently added to or reduced their stakes in the business. Ardsley Advisory Partners bought a new position in Catalyst Biosciences during the fourth quarter valued at $205,000. Renaissance Technologies LLC lifted its position in Catalyst Biosciences by 6.5% during the fourth quarter. Renaissance Technologies LLC now owns 355,373 shares of the biopharmaceutical company’s stock valued at $4,847,000 after purchasing an additional 21,600 shares during the last quarter. Virtu KCG Holdings LLC bought a new position in Catalyst Biosciences during the second quarter valued at $103,000. Bank of New York Mellon Corp bought a new position in Catalyst Biosciences during the second quarter valued at $107,000. Finally, Geode Capital Management LLC bought a new position in Catalyst Biosciences during the fourth quarter valued at $379,000. Institutional investors and hedge funds own 22.90% of the company’s stock.

Shares of Catalyst Biosciences (CBIO) traded down $0.54 during trading hours on Wednesday, hitting $33.82. 545,151 shares of the company were exchanged, compared to its average volume of 528,192. Catalyst Biosciences has a 12-month low of $3.11 and a 12-month high of $37.00. The company has a market capitalization of $244.15, a price-to-earnings ratio of -2.58 and a beta of 2.68.

WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/02/14/catalyst-biosciences-inc-cbio-receives-average-rating-of-strong-buy-from-brokerages.html.

About Catalyst Biosciences

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply